These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37543122)

  • 21. Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection.
    Lange A; Thunberg U; Söderquist B
    BMC Infect Dis; 2023 Oct; 23(1):706. PubMed ID: 37858087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
    Gatti M; Andreoni M; Pea F; Viale P
    Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
    Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice.
    Hanses F; Dolff S; Trauth J; Seimetz M; Hagel S
    Antibiotics (Basel); 2022 Apr; 11(5):. PubMed ID: 35625206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
    Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
    Trials; 2022 May; 23(1):407. PubMed ID: 35578360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy.
    Frazier JD; Stoudenmire LL; Wagner JL; Thomas GM; Steele GM; Henao-Martínez AF; Franco-Paredes C; Chastain DB
    Int J Antimicrob Agents; 2023 Jul; 62(1):106842. PubMed ID: 37160242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
    Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
    Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections.
    Gatti M; Viale P; Cojutti PG; Zamparini E; De Paolis M; Giannella M; Pea F; Tedeschi S
    Int J Antimicrob Agents; 2023 May; 61(5):106773. PubMed ID: 36878410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dalbavancin: a new lipoglycopeptide antibiotic.
    Bailey J; Summers KM
    Am J Health Syst Pharm; 2008 Apr; 65(7):599-610. PubMed ID: 18359966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.
    Hidalgo-Tenorio C; Vinuesa D; Plata A; Martin Dávila P; Iftimie S; Sequera S; Loeches B; Lopez-Cortés LE; Fariñas MC; Fernández-Roldan C; Javier-Martinez R; Muñoz P; Arenas-Miras MDM; Martínez-Marcos FJ; Miró JM; Herrero C; Bereciartua E; De Jesus SE; Pasquau J
    Ann Clin Microbiol Antimicrob; 2019 Oct; 18(1):30. PubMed ID: 31629409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.
    Raad I; Darouiche R; Vazquez J; Lentnek A; Hachem R; Hanna H; Goldstein B; Henkel T; Seltzer E
    Clin Infect Dis; 2005 Feb; 40(3):374-80. PubMed ID: 15668859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections.
    Morrisette T; Miller MA; Montague BT; Barber GR; McQueen RB; Krsak M
    J Antimicrob Chemother; 2019 Aug; 74(8):2405-2416. PubMed ID: 31322694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center.
    Brescini L; Della Martera F; Morroni G; Mazzanti S; Di Pietrantonio M; Mantini P; Candelaresi B; Pallotta F; Olivieri S; Iencinella V; Castelletti S; Cocci E; Polo RG; Veccia S; Cirioni O; Tavio M; Giacometti A
    Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
    Esposito S; Noviello S; Leone S
    Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review and meta-analysis on the safety of dalbavancin.
    Monteagudo-Martínez N; Solís-García Del Pozo J; Ikuta I; Galindo M; Jordán J
    Expert Opin Drug Saf; 2021 Sep; 20(9):1095-1107. PubMed ID: 34042549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections.
    Wang Y; Wang J; Wang R; Li Y; Cai Y
    J Glob Antimicrob Resist; 2021 Mar; 24():72-80. PubMed ID: 33279683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.